Distinct subgroups of follicular dendritic cell sarcoma: insights from clinical, histologic and immunophenotypic characterization.
OpenAlex 토픽 ·
Histiocytic Disorders and Treatments
Cutaneous lymphoproliferative disorders research
CNS Lymphoma Diagnosis and Treatment
Follicular dendritic cell sarcoma (FDCS) is a rare neoplasm with morphologic and phenotypic features resembling those of normal follicular dendritic cells (FDCs).
- p-value p = 0.012
- p-value p < 0.001
APA
Hsin‐Ni Li, Ren Ching Wang, et al. (2026). Distinct subgroups of follicular dendritic cell sarcoma: insights from clinical, histologic and immunophenotypic characterization.. Virchows Archiv : an international journal of pathology. https://doi.org/10.1007/s00428-026-04518-x
MLA
Hsin‐Ni Li, et al.. "Distinct subgroups of follicular dendritic cell sarcoma: insights from clinical, histologic and immunophenotypic characterization.." Virchows Archiv : an international journal of pathology, 2026.
PMID
42043516
Abstract
Follicular dendritic cell sarcoma (FDCS) is a rare neoplasm with morphologic and phenotypic features resembling those of normal follicular dendritic cells (FDCs). FDCS has been classified into two distinct entities based on their association with Epstein-Barr Virus (EBV): classic FDCS (cFDCS) and EBV-positive inflammatory FDCS (EBV + IFDCS). Diagnosis relies on characteristic histopathology and immunohistochemistry using FDC markers and EBV in situ hybridization (EBER). This study aimed to compare the clinical presentations, histologic features, and immunoprofiles between these two entities in a Taiwanese cohort. We retrospectively reviewed histological features of in-house and consultation cases of FDCS. Immunohistochemistry with novel markers including serglycin (SRGN), FDC-secreted protein (FDCSP) was applied, together with conventional FDC markers (CD21, CD23, CD35) and EBER. Programmed death ligand-1 (PD-L1), a potential therapeutic marker, was additionally evaluated and scored. Clinical and histological parameters, inflammatory cell infiltration, mitotic rate, and PD-L1 tumor proportion score (TPS) were compared statistically. We identified 30 patients including 16 cFDCS and 14 EBV + IFDCS. The median age was 56 years old (range, 22-80), with a female preponderance in EBV + IFDCS. EBV + IFDCS occurred exclusively in extra-nodal sites, while cFDCS more commonly involved lymph nodes. EBV + IFDCS showed significantly higher PD-L1 TPS (p = 0.012), more prominent inflammatory cell infiltration (90.0% vs. 12.5%, p < 0.001) in the presence of germinal centers (50% vs. 6%, p = 0.012), and lower mitotic activity (0.5 vs. 2.5/10 HPFs, p = 0.002). We identified distinct clinical and histologic features, as well as differential PD-Ll expression between cFDCS and EBV + IFDCS, supporting their classification as separate entities. Further molecular studies are needed to investigate their pathogenesis.